Open AccessSurvival benefit of tamoxifen in male breast cancer: prospective cohort analysis
Author(s) -
Holm Eggemann,
Cosima Brucker,
Michael G. Schrauder,
Marc Thill,
Felix Flock,
Mattea Reinisch,
Serban-Dan Costa,
Atanas Ignatov
Publication year - 2020
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-020-0857-z
Subject(s) - medicine , tamoxifen , hazard ratio , prospective cohort study , breast cancer , oncology , cancer , proportional hazards model , surgery , confidence interval , gynecology
Due to the lack of prospective data, current treatment of male breast cancer (MBC) is based on information obtained from retrospective analysis or by extrapolation from studies on female patients. In this prospectively enrolled cohort study, we retrospectively examined the survival effect of tamoxifen in MBC patients.